Non-high-density lipoprotein cholesterol in patients with metabolic syndrome
| Autor: | Herbert Yu, Jian Huang, Terry C. Davis, Donna L. Carden, Estela M. Kennen, Roy C. Parish, Ishak A. Mansi |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Cross-sectional study Lipoproteins General Biochemistry Genetics and Molecular Biology Coronary artery disease chemistry.chemical_compound Risk Factors Internal medicine medicine Humans In patient Triglycerides Metabolic Syndrome business.industry Cholesterol Hypertriglyceridemia Cholesterol HDL General Medicine Cholesterol LDL medicine.disease Endocrinology Cross-Sectional Studies chemistry Cardiovascular Diseases lipids (amino acids peptides and proteins) Metabolic syndrome business Dyslipidemia Lipoprotein |
| Zdroj: | Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 56(7) |
| ISSN: | 1081-5589 |
| Popis: | Background Metabolic syndrome (MS) represents a cluster of cardiovascular risk factors that includes hypertriglyceridemia. Although low-density lipoprotein (LDL) cholesterol is the critical therapeutic target in patients with coronary artery disease, LDL cannot be calculated in those with excessive hypertriglyceridemia. Non-high-density lipoprotein (HDL) does not require LDL for calculation and may be an alternative therapeutic target in MS. The purpose of this study was to determine non-HDL cholesterol in relation to other lipid components and comorbidities in MS patients. Methods A cross-sectional chart review on 928 public hospital patients was performed. Results Metabolic syndrome was present in 53% of all patients. Among those with MS, 87% had triglyceride level of greater than 150 mg/dL, 85% had low HDL, 71% had LDL of greater than 100 mg/dL, and 74% had non-HDL of greater than 130 mg/dL. The level of non-HDL cholesterol, but not total cholesterol or LDL cholesterol, was significantly higher ( P < 0.05) and less at goal ( P < 0.0001) in patients with MS. Diagnoses of coronary artery disease, hypertension, obesity, dyslipidemia, and diabetes were significantly more prevalent in MS patients ( P < 0.0001). Conclusion Compared with those without MS, non-HDL level was significantly higher and undertargeted in patients with MS, in parallel with significantly higher prevalence of comorbidities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|